Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy

• Published in: Journal of pharmacy & pharmaceutical sciences Vol. 27; p. 13193
• Main Authors: Shafaati, Tanin, Gopal, Keshav
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.08.2024
• Subjects: Animals; cell death; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetic Cardiomyopathies - drug therapy; Diabetic Cardiomyopathies - metabolism; diabetic cardiomyopathy; energy metabolism; Forkhead Box Protein O1 - metabolism; Forkhead Transcription Factors - antagonists & inhibitors; Forkhead Transcription Factors - genetics; Forkhead Transcription Factors - metabolism; FoxO1; Humans; oxidative stress; Oxidative Stress - drug effects; Science archive; diabetic cardiomyopathy; cell death; energy metabolism; oxidative stress; FoxO1
• ISSN: 1482-1826; 1482-1826
• DOI: 10.3389/jpps.2024.13193

Cardiovascular disease including diabetic cardiomyopathy (DbCM) represents the leading cause of death in people with diabetes. DbCM is defined as ventricular dysfunction in the absence of underlying vascular diseases and/or hypertension. The known molecular mediators of DbCM are multifactorial, including but not limited to insulin resistance, altered energy metabolism, lipotoxicity, endothelial dysfunction, oxidative stress, apoptosis, and autophagy. FoxO1, a prominent member of forkhead box O transcription factors, is involved in regulating various cellular processes in different tissues. Altered FoxO1 expression and activity have been associated with cardiovascular diseases in diabetic subjects. Herein we provide an overview of the role of FoxO1 in various molecular mediators related to DbCM, such as altered energy metabolism, lipotoxicity, oxidative stress, and cell death. Furthermore, we provide valuable insights into its therapeutic potential by targeting these perturbations to alleviate cardiomyopathy in settings of type 1 and type 2 diabetes.